EGFR and non-small cell lung carcinoma: A phase I study (NCT04397962) of personalized peptide vaccines targeting mutant EGFR in non-small-cell lung cancer (NSCLC) demonstrated that the L858R and T790M mutations were immunogenic in four patients [1,12].